Early treatment outcome of bedaquiline plus optimised background regimen in drug resistant tuberculosis patients.

Aims: Bedaquiline (BDQ) has been recently approved for drug resistant tuberculosis with active drug safety monitoring under programmatic condition. The present study was conducted to evaluate safety, tolerability and efficacy of bedaquiline plus optimised background regimen.

Methods: A prospective study was conducted on cohort of pre-extensively drug resistant (XDR) and XDR pulmonary TB patients.